Manipal Institute of Virology, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Department of Biostatistics, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):999-1006. doi: 10.31557/APJCP.2021.22.4.999.
There is growing evidence for the possible use of microRNAs (miRNAs) in cancers as diagnostic as well as prognostic biomarkers in the present era of Personalized Medicine. The objective of the present systematic review and meta-analysis was to assess the prognostic role of microRNAs in uterine cervical cancers.
A systematic review and meta-analysis was carried out searching electronic databases for published articles between January 2009 and August 2020 based on standard systematic review guidelines. Meta-analysis was performed by pooling the hazard ratio (HR) with 95% confidence interval (CI) to assess the prognostic value of deregulated miRNAs by the random-effects model.
In the present meta-analysis, the aberrant expression of 14 microRNAs in 1,526 uterine cervical cancer cases before definitive therapy from 14 case-control studies were assessed. The pooled HR of two miRNAs, miRNA-155 and miRNA-224 which were upregulated in cervical cancer tissues was 1.76 (95% CI 1.27-2.45) revealing significant association with overall poor survival. Meanwhile, the pooled HR was 1.53 (95% CI 0.94-2.94) when all the deregulated miRNAs in cervical cancer tissues were evaluated. The pooled HR of downregulated miRNAs was 1.46 (95% CI 0.81, 2.64). Meanwhile, the pooled HR of three upregulated miRNAs-425-5p, 196a, 205 in the serum sample was 1.37 (95% CI 0.45 -4.20).
The downregulation of aberrant miRNAs was not associated with poor overall survival rates.
在个性化医疗时代,越来越多的证据表明微小 RNA(miRNAs)可作为癌症的诊断和预后生物标志物。本系统评价和荟萃分析的目的是评估 microRNAs 在子宫颈癌中的预后作用。
按照标准系统评价指南,检索了 2009 年 1 月至 2020 年 8 月发表的文章的电子数据库,进行了系统评价和荟萃分析。通过随机效应模型汇总风险比(HR)和 95%置信区间(CI)来评估失调 miRNA 的预后价值。
在本荟萃分析中,对 14 项病例对照研究中 1526 例明确治疗前子宫颈癌组织中 14 种 microRNAs 的异常表达进行了评估。两种 miRNA(miRNA-155 和 miRNA-224)在宫颈癌组织中上调的 HR 为 1.76(95%CI 1.27-2.45),与总体生存不良有显著相关性。同时,当评估所有宫颈癌组织中失调的 miRNA 时,HR 为 1.53(95%CI 0.94-2.94)。下调 miRNA 的 HR 为 1.46(95%CI 0.81,2.64)。同时,血清样本中三个上调的 miRNA-425-5p、196a、205 的 HR 为 1.37(95%CI 0.45-4.20)。
异常 miRNA 的下调与总体生存率降低无关。